Jennifer L. Clarke, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jennifer L. Clarke, MD, MPH

Assistant Professor of Clinical Neurology and Neurological Surgery, UCSF

Phone: (415) 353-2966 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

I am an academic neuro-oncologist involved in clinical care, clinical research and teaching. I have extensive experience as well as formal training in clinical trial development, implementation, and analysis, including investigator-initiated, sponsored, and multi-institutional consortium and cooperative group studies testing new treatments and treatment combinations in gliomas.
I am a Co-Associate Director of the Clinical Core for the new UCSF (P01) Program Project Grant to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma (GBM). I am a co-investigator in all of the current neuro-oncology therapeutic trials, as well as in several non-therapeutic studies in the areas of diagnosis, epidemiology, and quality of life. In addition, I am the principal investigator at UCSF for six active protocols.
I am study chair for a single-institution investigator-initiated study treating newly-diagnosed, subtotally resected low-grade gliomas with chemotherapy, everolimus alone or in combination with temozolomide; the treatment is selected based on molecular parameters of the patient’s tumor. This study incorporates both imaging and molecular objectives, in collaboration with colleagues from the BTRC. I am also the PI of a phase I dose-escalation study in collaboration with Memorial Sloan-Kettering, combining bevacizumab (an anti-VEGF antibody) with hypofractionated stereotactic radiation in recurrent malignant glioma. In addition to anti-tumor properties, it is thought that bevacizumab has some radio-protective properties, which may allow the stereotactic radiation dose to be escalated higher than would otherwise be tolerated. Another study is a multi-center, randomized phase II study from the ALLIANCE. It randomizes patients between three arms: an autologous heat-shock protein vaccine followed by bevacizumab at recurrence, an autologous heat-shock protein vaccine in combination with bevacizumab, or bevacizumab alone. An additional multi-center study tests a checkpoint inhibitor, MEDI4736, in combination with radiation in patients with newly-diagnosed GBMs that are MGMT unmethylated, or in combination with bevacizumab in patients with recurrent, bevacizumab-refractory GBMs.
In addition to these clinical trials, we have an ongoing longitudinal study assessing quality of life in patients with malignant gliomas undergoing initial therapy, for which I am coordinating analysis.

Education

California Institute of Technology (Caltech), Pasadena, CA, B.S., 1995, Chemistry, With Honor
University of California, San Francisco, M.D., 2002, Medicine
University of California, Berkeley, M.P.H., 2001, Health Policy and Mgmt
St. Mary’s Medical Center, San Francisco, 06/03, Intern, Internal Medicine
University of California, San Francisco, 06/06, Resident, Neurology
Memorial Sloan-Kettering Cancer Center, 06/08, Fellow, Neuro-oncology


Professional Experience

  • 6/95-8/97
    Combion, Inc.
  • 7/02-6/03
    St. Mary’s Medical Center, San Francisco Intern Medicine
  • 7/03-6/06
    University of California, San Francisco Resident Neurology
  • 7/05-6/06
    University of California, San Francisco Chief Resident Neurology
  • 7/06-6/08
    Memorial Sloan-Kettering Cancer Center Fellow Neuro-Oncology
  • 7/07-6/08
    Memorial Sloan-Kettering Cancer Center Chief Fellow Neuro-Oncology
  • 8/08-6/10
    University of California, San Francisco Assistant Clinical Professor of Neurology and Neurological Surgery (Division of Neuro-Oncology)
  • 8/10 – present
    University of California, San Francisco Assistant Professor of Clinical Neurology and Neurological Surgery (Division of Neuro-Oncology)

Honors & Awards

  • 1999
    Nomination for “An Outstanding Lecture” UCSF Class of 2001
  • 2000
    University Fellowship, UC-Berkeley
  • 2000
    Award for “An Outstanding Lecture” UCSF Class of 2002
  • 2001
    UCSF Class of 1966 Scholarship
  • 2003
    Intern of the Year, St. Mary’s Medical Center
  • 2008
    ASCO Foundation Merit Award
  • 2009
    Awarded a fellowship to the 2nd Annual Clinical Trials Methods Course in Neurology, in Vail, Colorado, August 17-23, 2009; the course is sponsored by NINDS

Selected Publications

  1. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53.
    View on PubMed
  2. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  3. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361.
    View on PubMed
  4. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. Semin Radiat Oncol. 2014 Oct; 24(4):273-8.
    View on PubMed
  5. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):259-64.
    View on PubMed
  6. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40.
    View on PubMed
  7. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90.
    View on PubMed
  8. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62.
    View on PubMed
  9. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9.
    View on PubMed
  10. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013 Jan; 15(1):91-6.
    View on PubMed
  11. Neoplastic myelopathy. Semin Neurol. 2012 Apr; 32(2):137-45.
    View on PubMed
  12. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012 Apr; 18(2):328-42.
    View on PubMed
  13. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
    View on PubMed
  14. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012 Feb; 7(2):382-5.
    View on PubMed
  15. Primary central nervous system lymphoma. Handb Clin Neurol. 2012; 105:517-27.
    View on PubMed
  16. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):26-31.
    View on PubMed
  17. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
    View on PubMed
  18. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9.
    View on PubMed
  19. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24.
    View on PubMed
  20. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep; 99(2):283-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI